Drug Trial Radar · NCT05642585
A Study of Single-dose MY008211A in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Sep 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
May 27, 2022
Primary completion
Jun 4, 2023
Study completion Jun 4, 2023
Sponsor
- Lead sponsor
- Wuhan Createrna Science and Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The trial is the first human trial. The safety, tolerability, PK and PD of MY008211A Tablets will be evaluated in healthy subjects.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
MY008211A tabletsDrug
Single oral
PlaceboDrug
Single oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of adverse events to assess safety and tolerabilityTime frame: up to 21days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Hospital of Changsha
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.